Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

60.74USD
23 Feb 2018
Change (% chg)

$-0.15 (-0.25%)
Prev Close
$60.89
Open
$61.07
Day's High
$61.96
Day's Low
$59.81
Volume
226,007
Avg. Vol
307,340
52-wk High
$190.74
52-wk Low
$55.02

Chart for

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $3,303.16
Shares Outstanding(Mil.): 54.38
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion

* TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION

Jan 12 2018

Exclusive: U.S. cancer drugmaker Ignyta in advanced sale talks - sources

Ignyta Inc is in advanced talks to sell itself, people familiar with the matter said on Thursday, just three years after the U.S. cancer drugmaker became a public company focused on precision drugs and diagnostics.

Dec 21 2017

BRIEF-Tesaro secures $500 million non-dilutive term loan financing

* Tesaro secures $500 million non-dilutive term loan financing

Nov 21 2017

BRIEF-Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

* Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

Nov 20 2017

BRIEF-Tesaro reports Q3 loss per share $0.47

* Q3 revenue $142.8 million versus I/B/E/S view $132.8 million

Nov 07 2017

BRIEF-Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy

* Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy

Oct 26 2017

BRIEF-Evotec, Tesaro enter partnership on novel immuno-oncology agents

* dgap-news: evotec and tesaro enter strategic partnership to discover novel immuno-oncology agents

Oct 26 2017

FDA approves intravenous version of Tesaro drug for chemotherapy nausea

Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

Oct 25 2017

FDA approves intravenous version of Tesaro drug for chemotherapy nausea

Oct 25 Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

Oct 25 2017

Tesaro's ovarian cancer drug gets EU agency backing

A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

Sep 15 2017

Earnings vs. Estimates